Mining the adenovirus virome for oncolytics against multiple solid tumor types.

Area of Science:

• Oncolytic virotherapy
• Adenovirus serotypes
• Cancer treatment

Background:

• Adenovirus serotype 5 (Ad5) is widely used in cancer clinical trials.
• High seroprevalence of Ad5 poses immunological challenges for efficacy.
• Alternative adenovirus serotypes require evaluation for oncolytic potential.

Purpose of the Study:

• To compare the oncolytic potential of Ad5 with 13 other adenovirus serotypes.
• To assess adenovirus efficacy in immunocompetent and immunodeficient models.
• To identify promising adenovirus serotypes for cancer therapy.

Main Methods:

• Comparative analysis of Ad5 and 13 other adenovirus serotypes (species B, C, D, E).
• Evaluation of oncolytic potential in immunodeficient mouse models.
• Assessment in immunocompetent hamster models.

Main Results:

• Adenoviruses from species D demonstrated limited efficacy against solid tumors.
• Adenovirus 6 (Ad6) and Adenovirus 11 (Ad11) exhibited anti-cancer activity comparable to Ad5.
• Lower seroprevalence of Ad6 and Ad11 may overcome pre-existing immunity.

Conclusions:

• Ad6 and Ad11 are promising candidates for oncolytic virotherapy.
• Ad6-based therapies show potential for treating breast, ovarian, kidney, and liver tumors.
• Exploring alternative adenovirus serotypes can enhance oncolytic efficacy in diverse patient populations.